Summary
Even after successful surgery intended as curative, up to 90% of patients with pancreatic cancer suffer a relapse. Adding sorafenib to gemcitabine as adjuvant therapy for patients after R1 resection for pancreatic cancer does not improve disease-free survival or overall survival compared with GEM alone. This article presents results from the phase 2b CONKO-006 study.
- Adjuvant/Neoadjuvant Therapy
- Oncology Clinical Trials
- Cancers of the Accessory Digestive Organs
- Gastrointestinal Cancers
- Adjuvant/Neoadjuvant Therapy
- Oncology
- Oncology Clinical Trials
- Cancers of the Accessory Digestive Organs
- Gastrointestinal Cancers
- © 2014 MD Conference Express®
Tools
SOR as Adjuvant Therapy after Resection for Pancreatic Cancer Does Not Improve DFS
Permalink:
Table of contents
Cited By...
- No citing articles found.